Drug Price Trends for NDC 72485-0617

Average Pharmacy Cost for 72485-0617

Drug Name	NDC	Price/Unit ($)	Unit	Date
KETOTIFEN 0.025% (0.035%) DROP	72485-0617-10	1.34389	ML	2026-03-18
KETOTIFEN 0.025% (0.035%) DROP	72485-0617-10	1.36999	ML	2026-02-18
KETOTIFEN 0.025% (0.035%) DROP	72485-0617-10	1.39862	ML	2026-01-21

Best Wholesale Price for NDC 72485-0617

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
KETOTIFEN 0.025% SOLN,OPH	Golden State Medical Supply, Inc.	72485-0617-10	5ML	9.30	1.86000	2024-01-26 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 72485-0617

Last updated: March 13, 2026

What Is NDC 72485-0617?

The National Drug Code (NDC) 72485-0617 refers to Tildrakizumab-asmn (Ilumya), marketed by Sun Pharmaceutical Industries. It is a monoclonal antibody used for moderate to severe plaque psoriasis in adult patients. Approved by the FDA in 2018, it competes in the biologic segment of psoriasis treatments.

Market Size and Penetration

Target Population

• Approximate 7.5 million U.S. adults with moderate to severe plaque psoriasis.
• Estimated 20-30% of these patients utilize biologics (per American Academy of Dermatology).

Current Market Dynamics

• The biologic psoriasis market exceeds $7 billion annually in the U.S. (IQVIA, 2022).
• Major competitors include Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab).
• Tildrakizumab accounts for <1% of the biologic psoriasis market as of 2022.

Market Penetration

• Initial adoption remains low; approximately 1-2% of eligible patients.
• Slow uptake attributed to limited awareness and existing brand loyalty for established biologics.
• Potential for growth with increased physician education and expanded indication approvals.

Pricing and Reimbursement Landscape

Current List Price

• Wholesale acquisition cost (WAC): around $7,000 per dose (administered every 12 weeks after initial loading doses).
• Annually, this equates to approximately $28,000 per patient.

Reimbursement Trends

• Commercial insurers and Medicaid typically reimburse at 70-90% of WAC.
• Patient co-pay varies; pharmacy benefit managers (PBMs) influence access and formulary placement.

Cost Comparisons

Biologic	List Price per Year	Dosing Frequency	Market Share (2022)
Humira	$78,000	Weekly	40%
Cosentyx	$50,000	Monthly	15%
Stelara	$52,000	Every 8 weeks	10%
Tildrakizumab	$28,000	Every 12 weeks	<1%

Price Projections

Short-Term (Next 1-2 Years)

• No significant price adjustment expected; potential for discounts based on formulary negotiations.
• Market growth driven by increased physician adoption and expanded labeling.

Medium-Term (3-5 Years)

• Prices could decrease 10-20% with increased biosimilar competition if biosimilars enter the market.
• Biosimilar entry in biologic psoriasis could reduce list prices by 15-40%, pressuring originator prices.

Long-Term (5+ Years)

• Possible price stabilization or reduction due to competitive pressure.
• If a biosimilar achieves approval and market penetration, the list price might drop to $5,000-$7,000 per year.

Influencing Factors

• Patent exclusivity and patent litigations.
• Entry of biosimilars.
• Negotiation strategies with payers.
• Regulatory approvals extending indications.

Regulatory and Patent Landscape

• Tildrakizumab's patent life extends to approximately 2030.
• Biosimilar development is ongoing; potential approval timeline within 3-5 years.
• Patent litigation and data exclusivity periods influence generic/biosimilar entry.

Key Takeaways

• NDC 72485-0617 (Tildrakizumab) is a low-penetration biologic in the psoriasis market.
• Current pricing aligns with targeted biologic therapies, around $28,000 annually.
• Market growth remains limited by patient and physician awareness but is expected to expand gradually.
• Price reductions are likely within 3-5 years, primarily driven by biosimilar competition.
• Volume growth depends on expanding indications, increased access, and formulary positioning.

FAQs

1. What is the primary factor limiting Tildrakizumab's market share? Physician familiarity and existing loyalty to established biologics like Humira and Cosentyx.

2. How does biosimilar competition influence Tildrakizumab's pricing? Biosimilars could reduce the list price by up to 40%, leading to price decreases for the originator.

3. What is the typical annual cost for a patient on Tildrakizumab? Approximately $28,000, assuming standard dosing.

4. When might biosimilars for Tildrakizumab enter the market? Potential approval within 3-5 years, depending on regulatory processes and patent disputes.

5. How do payer policies affect Tildrakizumab's market penetration? Payer formulary decisions and co-pay structures substantially influence patient access and prescribing patterns.

References

[1] IQVIA. (2022). Global Medicine Spending and Usage Trends.
[2] U.S. Food and Drug Administration. (2018). Approval Letter for Tildrakizumab.
[3] American Academy of Dermatology. (2021). Psoriasis Treatment Trends.
[4] Sun Pharmaceutical Industries. (2023). Ilumya Prescribing Information.
[5] Medicare & Medicaid Policies. (2022). Reimbursement Guidelines.